Background：Necitumumab IMC-11F8, LY3012211 is a second-generation fully human immunoglobulin Ig G1 kappa isotype monoclonal antibody mAb that acts as an antagonist to direct against the extracellular region of epidermal growth factor receptor EGFR. It was developed by Eli Lilly & Co Indianapolis, IN, USA and produced in genetically engineered mammalian NS0 cells. It was first approved by the U.S. Food and Drug Administration FDA under the brand name Portrazza in 2015, for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. After that, it has gained the approval for marketing in the Europe Union and Japan respectively in 2016 and 2017. It is not indicated for treatment of non-squamous NSCLC. Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several di铿€erent settings. It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors TKIs and platinum-based chemotherapy.
